ROSSINI, Daniela
 Distribuzione geografica
Continente #
NA - Nord America 107
AS - Asia 95
EU - Europa 53
SA - Sud America 18
AF - Africa 2
OC - Oceania 2
Totale 277
Nazione #
US - Stati Uniti d'America 101
SG - Singapore 41
IT - Italia 17
CN - Cina 16
VN - Vietnam 13
DE - Germania 11
HK - Hong Kong 11
BR - Brasile 10
FI - Finlandia 8
IN - India 6
FR - Francia 5
AR - Argentina 3
CA - Canada 3
RU - Federazione Russa 3
SE - Svezia 3
AU - Australia 2
ES - Italia 2
ID - Indonesia 2
MX - Messico 2
PE - Perù 2
UY - Uruguay 2
BD - Bangladesh 1
CO - Colombia 1
CZ - Repubblica Ceca 1
EG - Egitto 1
IE - Irlanda 1
JM - Giamaica 1
JO - Giordania 1
KR - Corea 1
MY - Malesia 1
NL - Olanda 1
NP - Nepal 1
PK - Pakistan 1
PL - Polonia 1
TG - Togo 1
Totale 277
Città #
Singapore 19
San Jose 13
Hong Kong 11
Ashburn 9
Dallas 9
Ho Chi Minh City 7
Buffalo 5
Chandler 5
Rome 5
Beijing 4
Los Angeles 4
Munich 4
Nuremberg 4
Santa Clara 4
Turku 4
Helsinki 3
Lauterbourg 3
Shanghai 3
Toronto 3
Council Bluffs 2
Duino-Aurisina 2
Frankfurt am Main 2
Hanoi 2
Hillsboro 2
Jakarta 2
Lima 2
Milan 2
Millbury 2
Montevideo 2
Naples 2
Princeton 2
The Dalles 2
Woodbridge 2
Amman 1
Amsterdam 1
Andover 1
Aparecida de Goiânia 1
Atibaia 1
Barra de Guabiraba 1
Berazategui 1
Buenos Aires 1
Cairo 1
Camaragibe 1
Chanute 1
Conceição do Jacuípe 1
Decatur 1
Dublin 1
Duncan 1
Eagleville 1
Fairfield 1
Falkenstein 1
Federal 1
Genoa 1
Gopālganj 1
Gravatá do Ibiapina 1
Grosseto 1
Guangzhou 1
Hefei 1
Hisar 1
Itapipoca 1
Kahror Pakka 1
Lawrence 1
League City 1
Lomé 1
Mandeville 1
Melbourne 1
Mexico City 1
Minaçu 1
Mumbai 1
Norwalk 1
Odenton 1
Olomouc 1
Padua 1
Plano 1
Portão 1
Redondo Beach 1
Roubaix 1
Sacramento 1
Salt Lake City 1
San Francisco 1
Saravena 1
Seattle 1
Seoul 1
Sungai Buloh 1
Sydney 1
São Paulo 1
Thrissur 1
Torrevecchia Pia 1
Wilmington 1
Wroclaw 1
Totale 204
Nome #
Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO 131
FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials.ANNALS OF ONCOLOGY, ISSN: 0923-7534 76
Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA. Individual patient data pooled analysis of CRICKET and CAVE trials 69
null 13
Totale 289
Categoria #
all - tutte 856
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 856


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202216 0 0 0 0 1 0 6 0 2 1 3 3
2022/202319 5 2 0 1 3 2 0 2 4 0 0 0
2023/202429 1 3 5 3 1 2 0 3 1 6 2 2
2024/202571 0 3 3 2 6 6 2 4 13 7 10 15
2025/2026147 12 7 17 7 25 4 17 9 18 17 12 2
Totale 289